# Anastrozole Monotherapy Versus Maximal Oestrogen Blockade With Anastrozole and Fulvestrant Combination Therapy

> **NCT00256698** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 514 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Fulvestrant
- **DRUG:** Anastrozole

## Key facts

- **NCT ID:** NCT00256698
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-01
- **Primary completion:** 2009-04
- **Final completion:** 2012-02
- **Target enrollment:** 514 (ACTUAL)
- **Last updated:** 2012-08-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00256698

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00256698, "Anastrozole Monotherapy Versus Maximal Oestrogen Blockade With Anastrozole and Fulvestrant Combination Therapy". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00256698. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*